Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
30
Recruiting, any sponsor type, condition "diabetic macular edema"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed349
30 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).Pivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT07867080 · 514 participants (planned) · Start Sep 18, 2026 · Primary completion Jan 2029
Drug: 4D-150 IVT (3x10^10 vg); EYELEA ® (aflibercept) Injection 2 mg (0.05mL) · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Encino, California; Fullerton, California · 95 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07553429 · 49 participants (planned) · Start May 14, 2026 · Primary completion Mar 23, 2027
Drug: Low dose BI 3812465; Medium dose BI 3812465 and 1 more · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Scottsdale, Arizona; Arcadia, California · 29 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705555 · 960 participants (planned) · Start Aug 27, 2026 · Primary completion Oct 31, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Gilbert, Arizona; Glendale, California; Sacramento, California · 45 sites in all
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06962839 · 300 participants (planned) · Start Jun 5, 2025 · Primary completion Mar 1, 2028
Drug: BI 1815368; Placebo · For: Macular Edema
Sites: Phoenix, Arizona; Arcadia, California; Huntington Beach, California · 98 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705607 · 1,104 participants (planned) · Start Sep 25, 2026 · Primary completion Nov 30, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 31 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07425522 · 93 participants (planned) · Start Apr 21, 2026 · Primary completion Nov 17, 2028
Drug: RO7823653; Faricimab · For: Diabetic Macular Edema
Sites: Peoria, Arizona; Beverly Hills, California; Walnut Creek, California · 12 sites in all
Khadija Ahmed Mhrose GlalAcademic, hospital or other
NCT07917338 · 50 participants (planned) · Start Oct 28, 2026 · Primary completion Oct 1, 2027
Drug: NAC · For: Diabetic Macular Edema (DME)
Sites: Damietta, Egypt
- A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTOPivotal-lookingRecruiting
Kodiak Sciences IncIndustry
NCT07734844 · 910 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 31, 2028
Drug: Tabirafusp tedromer; Aflibercept (2.0 mg) · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Bakersfield, California; Glendale, California · 52 sites in all
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07592273 · 576 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 2028
Drug: Surabgene Lomparvovec; Sham and 2 more · For: Diabetic Retinopathy
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 40 sites in all
- A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaPivotal-lookingRecruiting
BioAge Labs, Inc.Industry
NCT07812090 · 180 participants (planned) · Start Aug 21, 2026 · Primary completion Nov 2027
Drug: Oral BGE-102; Oral Placebo Matching BGE-102 and 1 more · For: Diabetic Macular Edema (DME)
Sites: Bakersfield, California; Glendale, California; Mountain View, California · 16 sites in all
Jaeb Center for Health ResearchAcademic, hospital or other
NCT07567833 · 100 participants (planned) · Start Jul 31, 2026 · Primary completion Dec 2027
Drug: Anti-Vascular Endothelial Growth Factor · For: Diabetic Retinal Disease
Sites: Huntington Beach, California; Augusta, Georgia; Boston, Massachusetts · 8 sites in all
- Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular EdemaRecruiting
Massachusetts Eye and Ear InfirmaryAcademic, hospital or other
NCT07383701 · 36 participants (planned) · Start Jun 23, 2026 · Primary completion Jun 1, 2027
Drug: Lactobacillus plantarum 299v · For: Diabetic Macular Edema
Sites: Boston, Massachusetts
- Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 MicronsPivotal-lookingRecruiting
Belfast Health and Social Care TrustAcademic, hospital or other
NCT06985706 · 264 participants (planned) · Start May 19, 2025 · Primary completion Nov 30, 2028
Drug: Anti-VEGF Monotherapy (standard care) · For: Severe Diabetic Macular Oedema
Sites: Bedford, United Kingdom; Belfast, United Kingdom; Birmingham, United Kingdom · 22 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT07843849 · 20 participants (planned) · Start Apr 7, 2026 · Primary completion Mar 2028
Drug: Intravitreal dexamethasone implant; Intravitreal dexamethasone implant · For: Diabetic Macular Edema (DME); Diabetic Retinopathy
Sites: Nashville, Tennessee
Therini Bio Pty LtdIndustry
NCT06701721 · 21 participants (planned) · Start Dec 20, 2024 · Primary completion Mar 31, 2027
Drug: THN391 · For: Diabetic Macular Edema; Diabetic Retinopathy
Sites: Parramatta, Australia; Sydney, Australia; Westmead, Australia · 10 sites in all
OcugenIndustry
NCT05802329 · 24 participants (planned) · Start Jan 13, 2024 · Primary completion Jul 31, 2026
Drug: OCU200 · For: Center Involved Diabetic Macular Edema; Diabetic Macular Edema
Sites: Deerfield Beach, Florida; Erie, Pennsylvania; Bellaire, Texas · 5 sites in all
BayerBayer (BAYRY)
NCT07308639 · 50,000 participants (planned) · Start Mar 3, 2026 · Primary completion Dec 31, 2026
Drug: anti-VEGF medication · For: Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Sites: Leverkusen, Germany
- Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCTPivotal-lookingRecruiting
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityAcademic, hospital or other
NCT06610747 · 308 participants (planned) · Start Oct 28, 2024 · Primary completion Apr 30, 2027
Drug: Aflibercept 2Mg/0.05Ml Inj,Oph · For: Diabetic Macular Edema
Sites: Dongguan, China; Foshan, China; Guangzhou, China · 4 sites in all
- Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaPivotal-lookingRecruiting
Alvotech Swiss AGIndustry
NCT07489131 · 256 participants (planned) · Start Apr 22, 2026 · Primary completion Jul 2027
Drug: AVT29 (proposed aflibercept HD biosimilar); Eylea HD (aflibercept HD) · For: Diabetic Macular Edema
Sites: Budapest, Hungary
- Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabPivotal-lookingRecruiting
Osijek University HospitalAcademic, hospital or other
NCT07520045 · 100 participants (planned) · Start Mar 12, 2026 · Primary completion Jun 1, 2027
Drug: Faricimab; Biosimilar ranibizumab · For: Diabetic Retinopathy (DR); Diabetic Macular Edema (DME)
Sites: Osijek, Croatia
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular EdemaPivotal-lookingRecruiting
Bio-Thera SolutionsIndustry
NCT07515079 · 406 participants (planned) · Start Oct 9, 2024 · Primary completion Apr 30, 2027
Drug: BAT5906 injection; Lucentis · For: Diabetic Macular Edema (DME)
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 50 sites in all
Dr. Bryan StrelowAcademic, hospital or other
NCT07458061 · 10 participants (planned) · Start Feb 2026 · Primary completion Jun 2026
Drug: Placebo Tablet: BID; Kamuvudine K9 · For: Diabetic Macular Edema
Sites: Roanoke, Virginia
Vastra Gotaland RegionGovernment (non-federal)
NCT06984822 · 150 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 31, 2028
Drug: Anti-VEGF treatment · For: Diabetic Macular Edema; Visual Impairment; Diabetes Mellitus and 4 more
Sites: Mölndal, Sweden · 2 sites in all
- Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular EdemaPivotal-lookingRecruiting
Carmen ClappAcademic, hospital or other
NCT03161652 · 120 participants (planned) · Start May 24, 2017 · Primary completion Dec 2026
Drug: DME lactose pill; DME levosulpiride and 6 more · For: Diabetic Macular Edema; Diabetic Retinopathy
Sites: Querétaro City, Mexico · 2 sites in all
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Industry
NCT04187443 · 45 participants (planned) · Start Jun 2, 2020 · Primary completion Oct 30, 2026
Drug: MS-553 · For: Diabetic Macular Edema; Macular Edema; Type 2 Diabetes With Diabetic Macular Edema and 2 more
Sites: Changsha, China; Chengdu, China; Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.